A new industry partnership aims to achieve supply chain orchestration within closed system manufacturing for the cell and gene therapy sector.
The non-exclusive partnership brings together the respective expertise of TrakCel, a Welsh software developer for cell and gene therapy (CGT) supply chain tracking orchestration, and London-based innovator in cell and gene therapy manufacturing, Ori Biotech.
The Ori platform enables therapy developers and contract manufacturers to achieve automated CGT manufacturing in a closed platform.
The collaboration will enable users of the Ori Biotech manufacturing platform to benefit from live supply chain visibility through TrakCel software and TrakCel customers to have greater visibility into the manufacturing process via data services within the Ori platform.
Resulting from the agreement, TrakCel and Ori will develop suitable points of integration for a shared data platform to be available to partners.
“TrakCel has developed an extensive partnership network with contract manufacturers and companies across the cell and gene therapy sector. This enables therapeutic developers to be supported by more standardized and integrated solutions,” said Fiona Withey, co-founder and CEO of TrakCel.
“Closed system manufacturing is becoming progressively more important for the ongoing future of the cell and gene therapy sector, and we look forward to working with Ori to offer more integrated solutions to the wider industry.”
Farlan Veraitch, co-founder and CSO of Ori Biotech, added: “The integration of TrakCel’s advanced therapy supply chain tracking software with the Ori full-stack platform is another step forward enabling our customers to have full visibility throughout the supply chain.”